FirstWord Pharma

Vera kidney drug Trutakna shows strong final results in Phase 3 trial

Psychedelics Stock, Up 190% This Year, Flies High Again

Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial

Novartis cholesterol setback tests hopes for emerging heart disease drugs

Early Data Indicates an A.I.-Generated Drug Could Slow Aging

Teva autoimmune antibody notches ph. 2 win in celiac disease

Novartis inks $3.2B subcutaneous delivery deal with Alteogen

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

GSK plans phase 3 after mRNA flu vaccine beats standard shots

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review

Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

Biotech Scores Again With LSD In Anxiety; Stock Rises

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Regeneron backs $75M series A for antibody upstart Infinimmune

An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid

Silence Therapeutics aims at Takeda with new data in rare blood cancer

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

Study reveals new role for tau, a top target for Alzheimer’s drug development

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Eli Lilly to allow more patients to apply for special access to unapproved obesity drug

AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Argenx to Buy Forte Biosciences for $2.2 Billion

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.

Earnings live: AstraZeneca stock rises to kick off a busy earnings week

AstraZeneca shares rise after Q2 2026 earnings beat driven by strong cancer drug sales.

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

Patients aged six and older now have access to SIMTRIYO, the first new-class ADHD medication approved by the FDA in decades.

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

4 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Alzheimer's: Real-world study confirms Leqembi therapy benefits

FDA approval of an at-home subcutaneous injection for Leqembi marks a shift in the delivery of early Alzheimer's disease treatment.

Johnson & Johnson CFO Says Guidance Hike Is Just the Start

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.

Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion

French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.

New Drugs Are Replacing Chemo for Aggressive Breast Cancer

The FDA has granted broad first-line approval for Gilead's Trodelvy, signaling a shift away from traditional chemotherapy for aggressive breast cancer.

Ophthalmology venture grabs investors’ attention, raises $330 million

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers

Closely watched Pfizer lung cancer drug falls short in clinical trial

HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials

The U.S. Department of Health and Human Services is launching a department-wide effort to accelerate clinical trials and restore American leadership in medical research.